One of the main challenges in targeting Ligase IV for cancer therapy is the potential for off-target effects. Since Ligase IV is crucial for DNA repair in normal cells as well, its inhibition could lead to toxicity and adverse effects. Additionally, cancer cells might develop resistance to Ligase IV inhibitors, necessitating the use of combination therapies to achieve sustained therapeutic effects.
